• Ariel Izcovich, Diego Caruso, Matías Tisi Baña, Federico Bottaro, Javier Pollán, Ezequiel Saavedra, and Hugo N Catalano.
• Grupo CIERTO (Club interhospitalario de lectura crítica para recomendar basados en pruebas), Buenos Aires, Argentina.
• Medicina (B Aires). 2019 Jan 1; 79 (4): 315-321.

AbstractOne of the main pillars of acute ischemic stroke management is antiplatelet therapy. Different treatment schemes have been compared, suggesting that the combination of multiple antiplatelet drugs is associated with a reduced risk of stroke recurrence. However, it has also been associated with an increased risk of bleeding complications which, in the long term, surpass the mentioned benefits. However, considering that most stroke recurrences occur i n the short term, a time limited double antiplatelet scheme could result in significant benefits to patients with acute ischemic stroke. On this basis, we conducted a rapid systematic review of the literature in order to evaluate the effects of a short-term double antiplatelet therapy both on stroke recurrence and complications. All trials comparing double versus single antiplatelet therapy in patients with acute ischemic stroke were included. Results showed that double therapy reduces recurrence risk but probably marginally increases major bleeding complications. We suggest double antiplatelet therapy for the initial management of patients with minor (Score NIH < or equal to 3 or transient isquemic attack -TIA) acute ischemic stroke.

20 keywords...

hide…